Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. [artículo]
Por: Lahuerta Palacios, Juan José [Hematología y Hemoterapia]
.
Colaborador(es): Servicio de Hematología y Hemoterapia.
Editor: Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2013Descripción: 31(26):3279-87.Recursos en línea: Solicitar documento Resumen: PURPOSE: To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III studies in transplantation-eligible patients with previously untreated myeloma.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC7729 (Navegar estantería) | Disponible |
Formato Vancouver:
Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013 Sep 10;31(26):3279-87.
PMID: 23897961
Contiene 39 referencias
PURPOSE: To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III studies in transplantation-eligible patients with previously untreated myeloma.
No hay comentarios para este ejemplar.